• Our Vision

    To become the world-leading developer of novel drugs for tumor immunotherapy

  • Core values of us

    The values we believe in and also the codes of conduct we practice every day:

    • · Honest and diligent
    • · Open-minded and inclusive
    • · Humble and resilient
    • · Committed to becoming outstanding
  • Our Missions

    To develop novel drugs with good efficacy and low cost for doctors and patients; to create an excellent environment for employees to advance harmoniously, and create ever-increasing value for shareholders!!

OriCell Therapeutics

Founded in 2015, OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy. We have received a pre-A round exclusive investment of nearly 100 million yuan from Qiming Venture Partners at the end of 2019 and completed the A round of financing worth over 200 million Yuan at the end of 2020.

OriCell Therapeutics has made a large investment in the construction of 4 synergistic innovative product R&D technology platforms. Its long-term development strategy is to focus on the global unmet clinical needs for the treatment of liver cancer, ovarian cancer, gastric cancer, cervical cancer, and non-small cell lung cancer, and develop innovative cellular drugs and bispecific antibodies with high clinical values. Adhering to the vision of "becoming the world-leading developer of novel drugs for tumor immunotherapy", OriCell Therapeutics will continue to explore and make efforts to provide patients and doctors with safer and more effective tumor treatment solutions, and help patients "restore health and reset vitality".

Focus on the development of independent innovation product pipelines

  • At present, 10 independent innovation pipelines for cellular drugs and bispecific antibodies targeting solid tumors have been established. Six products for tumor immunotherapy have entered the stage of clinical development, and two core IND applications are currently underway.
  • We have reached a global development agreement with ANTENGENE (B.6996) regarding our independently developed bispecific antibody, which is worth 142 million USD. Presently, the clinical trial permission for this product has been issued in Australia;
  • The data from the exploratory clinical study on Ori®CAR-001 (Ori®CAR-C101), the first CAR T-cell product targeting liver cancer, have indicated that the product has high safety and development values. This product made its debut at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting;
  • The Ori®TIL-001 project related to the treatment of osteosarcoma was funded by the Science and Technology Commission of Shanghai Municipality. The exploratory clinical study data were released by oral and poster presentations at the 2021 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) and the 2021 Annual Meeting of the Connective Tissue Oncology Society (CTOS).

We own a B+A production and preparation center, an R&D center, and a quality inspection center, which collectively cover an area of 5000 m2.

  • Clinical-grade B+A production and preparation center

    Committed to establishing a fully automated, modularized and closed-type preparation and production environment, providing various types of research-grade, clinical-grade and traceable cell products.

  • Complete quality control system

    We have established standardized clinical operation protocols for biotherapy and standardized laboratory management policies, so as to improve the operating procedures and quality control specifications of each project.

  • Construction and planning of phase II clinical research facilities and commercial plants

    At present, the company has started the construction of a commercial production center in Life Science Blue Bay of Shanghai Lin-gang Special Area, covering an area of 31 acres, with a total investment of about 1 billion yuan, to accelerate the commercialization of immuno-oncology products. It is expected to pass EU GMP and China GMP certification and put into operation in 2023;

  • International market development plan

    In the future, the company plans to establish R&D, clinical research, and commercial operation centers in United States and other major international markets.

Environmental equipment

Continuous expansion of production sites and upgrade of environmental equipment to improve quality and efficiency